| FZD10 Gene | |
|---|---|
| Frizzled Class Receptor 10 | |
| Official Symbol | FZD10 |
| Full Name | Frizzled Class Receptor 10 |
| Chromosome | 12q14.1 |
| NCBI Gene ID | 8372 |
| Ensembl ID | ENSG00000111432 |
| OMIM ID | 605548 |
| UniProt ID | Q9ULW2 |
| Associated Diseases | Synovial Sarcoma, Cancer, Alzheimer's Disease, Parkinson's Disease |
| Protein Family | Class Frizzled GPCR (7-TM receptor) |
FZD10 (Frizzled Class Receptor 10) is a member of the Frizzled family of seven-transmembrane G protein-coupled receptors that serve as primary receptors for Wnt ligands. While FZD10 is best characterized for its role in cancer, particularly synovial sarcoma where it is frequently overexpressed, emerging evidence indicates that FZD10 also plays important roles in neural development and is relevant to neurodegenerative disease pathogenesis. FZD10 activates both canonical Wnt/β-catenin signaling and non-canonical Wnt pathways including planar cell polarity (PCP) and Wnt/Ca²⁺ signaling, with distinct expression patterns in the developing and adult nervous system. In the brain, FZD10 is expressed in neural stem cells, developing neurons, and select mature neuronal populations, where it regulates neurogenesis, neuronal differentiation, and synaptic function. Dysregulated FZD10 expression and Wnt signaling alterations have been implicated in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, making FZD10 a molecule of interest for understanding neurodegeneration mechanisms and developing therapeutic strategies [@l'italien2019].
The FZD10 gene is located on chromosome 12q14.1 and encodes a 695-amino acid protein with a molecular weight of approximately 77 kDa. Like other Frizzled receptors, FZD10 possesses the characteristic architecture of class F GPCRs with distinct functional domains:
The N-terminal cysteine-rich domain (CRD) of FZD10 contains 10 conserved cysteine residues forming disulfide bonds that create a compact ligand-binding module. The CRD specifically recognizes Wnt ligands with a distinctive binding profile compared to other Frizzled receptors. Structural studies have demonstrated that FZD10 has high affinity for Wnt5A and Wnt11, enabling robust activation of non-canonical Wnt pathways, while also binding Wnt3A for canonical signaling. The CRD determines ligand-binding affinity and specificity, making it a target for therapeutic intervention [1].
FZD10 contains seven hydrophobic transmembrane helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). The transmembrane domain adopts the canonical GPCR fold and can couple to heterotrimeric G proteins upon ligand binding. FZD10 exhibits coupling to multiple G protein subtypes depending on cellular context, including Gαs for cAMP signaling, Gαq for PLC activation, and Gαi/o for downstream effects on PI3K/Akt signaling.
The intracellular C-terminal tail contains a PDZ domain-binding motif (Ser/Thr-X-Ser/Thr-X-φ) that enables interaction with Dishevelled (DVL) adaptor proteins and other signaling components including scaffold proteins and regulatory enzymes. This tail region undergoes post-translational modifications including phosphorylation that modulate receptor activity and protein-protein interactions.
FZD10 activates the canonical Wnt/β-catenin pathway through ligand binding and receptor complex formation:
Receptor Activation: Wnt ligand binding to the FZD10 CRD initiates receptor oligomerization and recruitment of cytoplasmic signaling proteins. FZD10 forms receptor complexes with co-receptors LRP5 or LRP6, which are required for full pathway activation. The FZD10-LRP5/6 complex internalized into signaling endosomes creates a platform for downstream signal transduction.
Signalosome Formation: Upon activation, FZD10 recruits Dishevelled (DVL1, DVL2, DVL3) proteins through interactions between the C-terminal tail of FZD10 and the PDZ domain of DVL. DVL phosphorylation and polymerization create a "signalosome" that inhibits the β-catenin destruction complex.
β-catenin Stabilization: FZD10-activated DVL disrupts the destruction complex containing APC, AXIN1/2, GSK3β, and CK1α, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it associates with TCF/LEF transcription factors.
FZD10 also activates non-canonical Wnt pathways:
Wnt/PCP Pathway: The planar cell polarity pathway regulates cytoskeletal dynamics, cell polarity, and tissue patterning. FZD8 activation recruits DVL and activates small GTPases including RAC1 and RHOA, leading to effects on actin cytoskeleton organization, cell migration, and neuronal morphogenesis.
Wnt/Ca²⁺ Pathway: FZD10 can activate downstream signaling through Gαq-coupled phospholipase C (PLC) activation, leading to intracellular Ca²⁺ release and activation of Ca²⁺-dependent kinases including CaMKII and PKC.
FZD10 exhibits developmental stage-specific expression in the nervous system:
The temporal pattern of FZD10 expression suggests roles in early neural specification and progenitor maintenance, with decreased expression in adulthood [2].
FZD10 signaling promotes neuronal differentiation from neural stem cells:
While less studied than other Frizzled receptors, FZD10 likely contributes to synaptic development:
Emerging evidence links FZD10 and Wnt signaling to Alzheimer's disease pathogenesis:
Post-mortem studies and model systems reveal:
FZD10 signaling interacts with amyloid-β pathology:
Wnt/FZD10 signaling intersects with tau pathology:
Modulating FZD10 represents a potential AD therapeutic strategy:
FZD10 and Wnt signaling have implications for Parkinson's disease:
FZD10 may contribute to dopaminergic neuron function:
FZD10 intersects with mitochondrial dysfunction in PD:
The relationship between alpha-synuclein and FZD10:
FZD10-based approaches for PD:
FZD10 and Wnt signaling dysregulation in ALS:
Studies of ALS tissue and models reveal:
FZD10 may relate to selective motor neuron vulnerability:
While this section focuses on neurodegeneration, FZD10 was first characterized in cancer:
FZD10 is frequently overexpressed in synovial sarcoma:
FZD10 expression in other malignancies:
FZD10 exhibits tissue-specific and development-specific expression:
Brain Regions:
Cell Types:
Development:
FZD10 interacts with multiple proteins:
| Ligand | Pathway | Expression Pattern |
|---|---|---|
| Wnt5A | PCP, Wnt/Ca²⁺ | Developmental, cancer |
| Wnt11 | PCP | Developmental |
| Wnt3A | Canonical | Developmental |
FZD10 genetic variants in neurodegenerative diseases:
FZD10 as a therapeutic target:
FZD10 as a biomarker:
Research priorities for FZD10 in neurodegeneration:
FZD10 serves as a Wnt receptor with important functions in neural development and emerging relevance to neurodegenerative diseases. While best characterized in cancer biology, particularly synovial sarcoma, FZD10 plays roles in neural stem cell biology, neuronal differentiation, and synaptic function in the developing and adult nervous system. Dysregulated FZD10 expression and Wnt signaling alterations contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and ALS, intersecting with core pathological features including protein aggregation, mitochondrial dysfunction, and neuroinflammation. The therapeutic targeting of FZD10 and Wnt signaling represents a promising strategy for disease modification in neurodegenerative conditions, though significant challenges remain in developing brain-penetrant, pathway-specific modulators with appropriate safety profiles. Continued investigation of FZD10 biology in the context of neurodegeneration offers substantial potential for advancing treatment strategies for these devastating disorders.
Beyond AD, FZD10 and Wnt signaling are relevant to other tauopathies including progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia:
Wnt/FZD10 signaling modulates neuroinflammatory responses:
FZD10 contributes to synaptic biology:
Adult neurogenesis and FZD10:
Wnt/FZD10 intersects with mitochondrial function:
FZD10 and Wnt signaling in axonal transport:
FZD10 intersects with proteostasis:
Wnt/FZD10 and oxidative stress:
Age-related changes in FZD10:
FZD10 in non-neuronal cells:
FZD10 as a biomarker:
FZD10-targeted therapies:
Antalis MC, et al. FZD10 in cancer and development. 2010. ↩︎
Nishimura M, et al. FZD10 in brain development. 2015. ↩︎
Inestrosa NC, et al. Wnt signaling in Alzheimer's disease. 2013. ↩︎
Garrido J, et al. Wnt dysfunction in ALS. 2019. ↩︎
Xie Y, et al. "FZD10 in synovial sarcoma oncogenesis." Oncogene. 2021. ↩︎
Marchetti B, et al. Wnt/beta-catenin in neuroinflammation. 2018. ↩︎